{"name":"Hebei Senlang Biotechnology Inc., Ltd.","slug":"hebei-senlang-biotechnology-inc-ltd","ticker":"","exchange":"","domain":"hebeisenlangbiotechnology.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Autologous CD7-targeting CAR T cells","genericName":"Autologous CD7-targeting CAR T cells","slug":"autologous-cd7-targeting-car-t-cells","indication":"T-cell acute lymphoblastic leukemia (T-ALL)","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Senl-h19 CAR-T","genericName":"Senl-h19 CAR-T","slug":"senl-h19-car-t","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Autologous CD7-targeting CAR T cells","genericName":"Autologous CD7-targeting CAR T cells","slug":"autologous-cd7-targeting-car-t-cells","phase":"phase_2","mechanism":"Autologous CD7-targeting CAR T cells are engineered patient-derived T cells that recognize and kill CD7-expressing cells, primarily used to target T-cell malignancies.","indications":["T-cell acute lymphoblastic leukemia (T-ALL)","Peripheral T-cell lymphomas"],"catalyst":""},{"name":"Senl-h19 CAR-T","genericName":"Senl-h19 CAR-T","slug":"senl-h19-car-t","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDBXZ243SnRELU9tTG5VZTBBaUFIQkVwVmJEYW42OGc5emVxOWVhSGlZcng5U1RDZE5IWUM5YUdYRE1VSDBpVFZxTW5iNUF0X29DSUlDa3RBaHpKRmhwODNuU1hlRmEyQzNDLU9VUlVYN29vb3dTZFl1T21FU2FWNXpGZklzS2hZQXNoV21KczXSAZYBQVVfeXFMTmdVSG5xdU5Qa2JKdFpoQWYyaHhkUkxfM1FUdmljWjc5Z2VZYkxxRzhsa0VmZWZXc2h1UWY4MFFibXlwbXplT0VBS2dITk5ya1oxVlRwN3JJUF9fOFkwQlZ5eHB1NmNwRWZQV0NvMVlmSDZka3laZlZTMjNaN1FXdWxiU0hUSC1XckpWb09qRGNVSDI3UXdR?oc=5","date":"2026-01-17","type":"pipeline","source":"BioInformant","summary":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide - BioInformant","headline":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNdGJiX1hIRnBfajZ4OUVpTXN3X1RHTUNnT1RLdUFOSGlGbHN5NjVnbll1a1h4UEVpNjNHcURnUF9xb1pVM2pwX2JVVFlnWHh6SU9LOFh3U0Zwd1FXZmxpVXpvbHZtcGRhTU14YmxudmF3azRzckJlYUpvZ2dlN2NJbTFPYkdIaTFLVHhOTTZBZWRSNlB5LTQ5UnJOeHlGeUpaVTkwNERUYi02blpuUHhPdjhBZ3p6NTRLTlNLdFZ5Slh6YVlCblhXTGdzYjNEMHMwY0ZwZDV0MDBoU3p5V1RQTnpHb1I1NUJmTGotckNWZzQwSFdTVUdYaFc4S29yWWc5Q1pnTTZib1VxLTRHSmUzbUprc0c1OEdpN2JtZzd1MUxLMm1SNDhjMERR?oc=5","date":"2025-07-07","type":"trial","source":"globenewswire.com","summary":"Bispecific Antibody Clinical Trial Pipeline Gains Momentum: - globenewswire.com","headline":"Bispecific Antibody Clinical Trial Pipeline Gains Momentum:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQV1JBcWNmYk85cFJyVU9PYzE1c0x3b2RjcW9fN1JUQ1FNc1BRUjNMRkltMTl3cHZCdnpoOHFvQlFCY3BrQ0ZWa1lxQnNCb055NlZyVlcwelZGd1hxRmhCVnBybXdSS1B3eFJZT1JUV0JfWGFEM2Vvc3ZJNzdRdUlPcmR4YkJjSEEyWGhIYm0xZkk0cXJLTzNXeXR3anY5cjA4eEQwbzNVWjUtSWxDdm55Ti0zWFh3TW8zUnlRcmpVTFhQc0NCMmJydTdVUzBYbXdGbGR5R2xPeWNLX3VuV0t6bWduNW1GYnhSYl8zbmFfa2lteDBGTzNtQUlKNHlOczZjYXFISHdpc3dtUm9IY0FCNmQwZ2hPeEhYdTAwaFFwTXlGd2Z4NHdpbUxiZXU1dGM5UjBrVjQ2UTc5QlJkM0NyUVlQWnBQTkU?oc=5","date":"2025-03-05","type":"trial","source":"globenewswire.com","summary":"CAR T-cell Therapy Clinical Trial Pipeline Experiences - globenewswire.com","headline":"CAR T-cell Therapy Clinical Trial Pipeline Experiences","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}